China’s biotech firms challenge US with rapidly developing RAS-targeted cancer therapies
When the shares of Revolution Medicines surged after the US biotech firm unveiled a landmark result – its drug nearly doubled the overall survival for late-stage pancreatic cancer patients to 13.2 months – investment banks and scientists flagged that the company’s Chinese rivals racing to target the same cancer mutation are significantly undervalued by the market. Chinese biotech firms were closing the gap with the United States as the country “has developed a highly competitive and rapidly...
Read the full story at Business - South China Morning Post →EUROS aggregates the world's financial press. The full article lives with the newsroom that reported it.
